The steady stream of positive news coming from the EU's CHMP today did not extend to Isis Pharmaceuticals (IONS -1.44%) and Sanofi (SNY 5.90%). Unfortunately, the duo's drug Kynamro, which is FDA-approved for the treatment of Homozygous Familial Hypercholesterolaemia in the United States, failed to win the green light from the CHMP for the second time.
What does this mean for Isis and Sanofi? And does this make Isis more vulnerable to its competitor Aegerion Pharmaceuticals (NASDAQ: AEGR)? Health-care analyst Max Macaluso dives into these issues in the following video.
